Iran Pharmacy Ph.D. Entrance Exam case studies
Iran Pharmacy Ph.D. Entrance Exam · Put your knowledge to work in context.
entrance examination in pharmaceutical sciences (آزمون ورودی دکتری تخصصی داروسازی) is the competitive, subject-based admission test used by Iranian universities to screen applicants for doctoral-level study and research training in pharmacy-related fields. It is aimed at graduates with a pharmacy or closely related life-sciences background who want to pursue doctoral research, specialist training, or an academic career. The Iran Pharmacy Ph.D. Entrance Exam case studies are 5 cases and about 4,336 words.
1Extended-release matrix tablet of a weakly basic BCS Class II drug: why exposure halves in the fasted gut
Your company is developing a 100 mg extended-release matrix tablet of compound X, a weak base (pKa 8.4, logP 3.1) with high Caco-2 permeability (18 x 10^-6 cm/s) and aqueous solubility of 6.0 mg/mL at pH 1.2 but only 0.03 mg/mL at pH 6.8. The formulation contains 30% w/w HPMC K100M with microcrystalline cellulose and lactose; no pH-modifying excipient is included.
830 words, about 4 min2Warfarin, a urinary tract infection and a supra-therapeutic INR in a patient with a mechanical valve
A 71-year-old woman with a mechanical mitral valve and atrial fibrillation takes warfarin 5 mg daily. Her INR has been stable between 2.4 and 3.0 for eight months.
757 words, about 4 min3A related-substances HPLC method that fails mass balance and disagrees between laboratories
A stability-indicating HPLC method for an immediate-release API (maximum daily dose 800 mg) uses a 150 x 4.6 mm, 5 micrometre C18 column, isocratic 50:50 acetonitrile : 25 mM phosphate buffer pH 3.0 at 1.0 mL/min, detection at 240 nm, run time 20 min. At the initial time point the assay is 99.2% by the method, but total mass balance (assay plus all impurities) is only 88%.
944 words, about 5 min4A bioequivalence study that misses the Cmax interval with 42% within-subject variability
A two-sequence, two-period, two-treatment crossover bioequivalence study of a 400 mg modified-release tablet was run in 24 healthy fasted volunteers with a seven-day washout and full-profile sampling to 72 h. Twenty-three subjects completed; one withdrew after period 1 because of vomiting.
830 words, about 4 min5Rescuing a potent lead from hERG liability without losing target potency
A discovery programme has a lead compound, A, that inhibits its peripheral G-protein-coupled receptor target with an IC50 of 20 nM. A is a tertiary amine with pKa 9.1 and logD7.4 of 4.6.
975 words, about 5 min